Newsroom

Strive to Deliver Breakthroughs

  1. February 05, 2025

    Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — February 4, 2025   Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceuti...

    View more
  2. January 10, 2025

    Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases

    Cambridge, MA, Rotterdam, NL, Shanghai, CN — January 10, 2025   Harbour BioMed (HKEX: 02142, the “Company”), a global biophar...

    View more
  3. November 15, 2024

    Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — November 14, 2024   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceuti...

    View more
  4. November 08, 2024

    Harbour BioMed Announces Submission of IND Application for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – November 8, 2024   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutic...

    View more
  5. October 10, 2024

    Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — October 9, 2024   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical...

    View more
  6. September 14, 2024

    Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — September 14, 2024   Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceuti...

    View more
  7. August 28, 2024

    Harbour BioMed Announces 2024 Interim Results

    Harbour BioMed (“HBM”, or the "Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and c...

    View more
  8. July 26, 2024

    Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

    Cambridge, MA, Rotterdam, NL, Suzhou, CN — July 25, 2024   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...

    View more
  9. July 19, 2024

    Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – July 19, 2024   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...

    View more
  10. June 27, 2024

    Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – June 27, 2024   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...

    View more